Your browser doesn't support javascript.
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.
Heil, Emily L; Claeys, Kimberly C; Kline, Ellen G; Rogers, Tara M; Squires, Kevin M; Iovleva, Alina; Doi, Yohei; Banoub, Mary; Noval, Mandee M; Luethy, Paul M; Shields, Ryan K.
  • Heil EL; Department of Practice, Science, and Health Outcomes Research, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, USA.
  • Claeys KC; Department of Practice, Science, and Health Outcomes Research, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, USA.
  • Kline EG; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Rogers TM; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Squires KM; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Iovleva A; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Doi Y; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Banoub M; Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
  • Noval MM; Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
  • Luethy PM; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Shields RK; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
J Antimicrob Chemother ; 78(4): 1034-1040, 2023 04 03.
Article in English | MEDLINE | ID: covidwho-2262606
ABSTRACT

OBJECTIVES:

We evaluated the clinical characteristics and outcomes of patients with COVID-19 who received three-drug combination regimens for treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections during a single-centre outbreak. Our objective was to describe the clinical outcomes and molecular characteristics and in vitro synergy of antibiotics against CRAB isolates. MATERIALS AND

METHODS:

Patients with severe COVID-19 admitted between April and July 2020 with CRAB infections were retrospectively evaluated. Clinical success was defined as resolution of signs/symptoms of infection without need for additional antibiotics. Representative isolates underwent whole-genome sequencing (WGS) and in vitro synergy of two- or three-drug combinations was assessed by checkerboard and time-kill assays, respectively.

RESULTS:

Eighteen patients with CRAB pneumonia or bacteraemia were included. Treatment regimens included high-dose ampicillin-sulbactam, meropenem, plus polymyxin B (SUL/MEM/PMB; 72%), SUL/PMB plus minocycline (MIN; 17%) or other combinations (12%). Clinical resolution was achieved in 50% of patients and 30-day mortality was 22% (4/18). Seven patients had recurrent infections, during which further antimicrobial resistance to SUL or PMB was not evident. PMB/SUL was the most active two-drug combination by checkerboard. Paired isolates collected before and after treatment with SUL/MEM/PMB did not demonstrate new gene mutations or differences in the activity of two- or three-drug combinations.

CONCLUSIONS:

Use of three-drug regimens for severe CRAB infections among COVID-19 resulted in high rates of clinical response and low mortality relative to previous studies. The emergence of further antibiotic resistance was not detected phenotypically or through WGS analysis. Additional studies are needed to elucidate preferred antibiotic combinations linked to the molecular characteristics of infecting strains.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Acinetobacter Infections / Acinetobacter baumannii / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2023 Document Type: Article Affiliation country: Jac

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Acinetobacter Infections / Acinetobacter baumannii / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2023 Document Type: Article Affiliation country: Jac